Logo

Prevention Of HIV & Messages for COVID-19: Lessons Learned over 40 Years - Shared screen with speaker view
Kenneth Mayer
12:43
Hi Mike. looking forward to your talk
Kathryn Stephenson
16:41
Hi everyone! Anyone who has questions for the panel, please put them in the chat! Boris and I will take a look and bring them up when Dr. Cohen is done!
HU CFAR
19:32
Hi Clifford, if you have a question, submit it in the chat. thanks
HU CFAR
21:49
Hi everyone! Anyone who has questions for the panel, please put them in the chat! Boris and I will take a look and bring them up when Dr. Cohen is done!
Lucy Mupfumi
26:44
Dr Cohen, you mentioned that TDF non-adherence is forgiving in man, and not so much in women. Could you explain why this is?
Robert Weinberg
29:47
With reports of new strains of Covid-19, what is the risk that the current vaccines may not cover novel strains appearing?
Mark Ingaciola
47:55
What do you think about vectored delivery of bNAbs (combos)? Is that the way to get to a vaccine?
Kenneth Mayer
48:45
Great talk, Mike. do you think bnAb's will be scalable globally from a cost standpoint?
HU CFAR
53:10
no problem if you want to stay on a bit longer. it is up to you
Kathryn Stephenson
53:37
It’s supposed to end at 1pm?
Galit Alter
55:37
If prep works… why do we need antibodies? Can mike help make sense of this?
Galit Alter
57:06
Can mike comment on why the antibodies work early but not late for covid?
Galit Alter
01:00:33
What about combos of antibodies+Jakinhib+dex?
Galit Alter
01:02:17
You got Boris and katie!
Mark Ingaciola
01:02:21
Your panel is Boris and Katy!
Galit Alter
01:02:24
Raj and I get to be enterained!
Mark Ingaciola
01:02:34
I don't think we can join!
Galit Alter
01:03:00
Will antibodies block the development of immunity for both HIV and COVID?
HU CFAR
01:03:20
i gave you permission to talk
Galit Alter
01:03:43
Thanks! I need Katie/Boris to give me permission to ask a question ;)
Mark Ingaciola
01:03:56
Boris, what are your thoughts about the ability of the SIV model to guide which combinations of bNAbs should be put into AMP-2? I wish I was on the panel?
Mark Ingaciola
01:05:03
Katy, what is the status of your combination bNAb trials for treatment/cure in people with HIV?
Kathryn Stephenson
01:05:36
I don’t know how to add anyone!
Galit Alter
01:05:47
Given what Mike’s seen (or not seen) in AMP- how do you feel about antibodies for cure???
Mark Ingaciola
01:06:02
Most of the resistance in people on PrEP have been seen with people had undiagnosed acute HIV
HU CFAR
01:07:19
this question if from Raj who's logged on with Mark's link: Most of the resistance in people on PrEP have been seen with people had undiagnosed acute HIV
Galit Alter
01:12:39
Thank you!!!